Compare Moderna, Inc. (MRNA) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tractor Supply Co — how do they compare? Moderna, Inc. trades at $63.94 (market cap $24.18B), while Tractor Supply Co trades at $36.27 (market cap $18.39B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Tractor Supply Co pays a 2.72% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TSCO | |
|---|---|---|
Market Cap | $24.18B | $18.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $62.65 |
52-Week Low | $22.36 | $29.14 |
Enterprise Value | $20.33B | $24.70B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
TSCO trades at $34.62, up 0.17% today, with a bullish technical signal from moving averages but bearish oscillators. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue has grown steadily from $14.2B in 2022 to $15.5B in 2025, though net income margin has declined. Recent news highlights cost pressures and a lowered 2026 outlook, alongside strategic initiatives like pet product expansion and dividend payments.
The outlook is mixed: a consensus price target of $36.29 suggests modest upside, but near-term headwinds from weak discretionary demand and higher costs pose risks. Long-term opportunities include digital growth and store investments, yet investor sentiment remains cautious amid earnings misses and guidance cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
